Laidlaw & Company (UK) Ltd specializes in investment banking services. The company also offers investment advice to its clients based on their personal as well as professional needs. The firm’s clients range from public and private ventures to wealthy investors. The FCA has licensed Laidlaw to operate in England and Wales under registration number 537165. The firm is a member of the prestigious Securities Investor Protection Corporation (SIPC). The SIPC offers account protection for all securities and cash for companies such as Laidlaw hold. Laidlaw & Company is also affiliated with Laidlaw International.
The CEO of Laidlaw & Company is Matthew Eitner while the head of capital markets and managing partner is James Ahern. Other executives include Hugh Regan, the private equity head, and director of investment banking and Craig Bonn, the senior managing director. Additionally, Hugh Marasa serves as the senior managing director in charge of private placements.
Laidlaw & Company (UK) Ltd recently expanded its London satellite office by adding two executives. These include Bryan Kobel, who will serve as the managing director of the company’s equity capital markets department and Richard Michalski, who will hold the position of senior managing director for the company’s wealth management unit.
Relmada Therapeutics filed a lawsuit against Laidlaw & Company (UK) Ltd in 2015. The lawsuit targeted Laidlaw’s senior executives James Ahern and Matthew Eitner. As providers of investment banking services, Laidlaw’s officials gained access to Relmada’s confidential business data. The officials then used this information to declare its interest in acquiring Relmada. Relmada filed this lawsuit since it believes Laidlaw’s officials violated both United States financial regulations and the SIPC regulations. Relmada wants Laidlaw senior executives, James and Matthew, to desist from damaging the company’s reputation using the confidential business information they acquired without consent.